ClinicalTrials.gg
Status unknownNCT04172961Updated Oct 20, 2022

Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days

A Phase 4 interventional study of nanomicellular cyclosporine 0.09% and Lifitegrast in Dry Eye, sponsored by Toyos Clinic. Status unknown at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-20.

Sponsored by Toyos Clinic · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This study will be a randomized, double-blind prospective in 3 clinical sites to compare the efficacy of two currently approved topical ophthalmic drops in the clearing central corneal staining in 90 days prior to elective cataract or LASIK surgery.

Read the detailed description

The study will be a randomized, double-blind prospective study in 3 sites in the US to compare efficacy of improvement in central corneal staining with fluorescein dye evaluations at slit lamp exam, secondarily improvement in OSDI questionnaire with additional questions regarding dysgeusia, blurriness, and sensation of burning, improvements in corneal topography and improvements in Schirmer's testing. 100 study subjects 18-85 male or female will be enrolled in the Nashville, Beverly Hills and St. Louis areas who are generally healthy with central corneal staining and scheduled for uncomplicated phacoemulsification or uncomplicated LASIK.

02

Conditions studied

  • Dry Eye

Browse trials for

03

In context

Dry Eye Syndromes

1,366 studies on the registry are indexed under Dry Eye Syndromes; 207 are open to participants now.

This study's planned enrollment of 100 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.

Browse Dry Eye Syndromes studies →

Lead sponsor

Toyos Clinic is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is able to read, understand and sign .
  2. Provision of signed and dated informed consent and HIPAA authorization .
  3. Willingness to comply with study procedures and availabilty for duration of study.
  4. Aged 18-85, male or female
  5. Minimum of 5 central corneal superficial punctate keratitis spots.
  6. Normal eyelid anatomy
  7. highly effective for at least 1 month prior to screening and agreement to use effective contraception during study participation and for an additional 4 weeks after study drug discontinuation.
  8. or surgical sterilization.

Exclusion criteria

-

Exclusion Criteria:

  1. Known or to product.
  2. Contact lens use within one month prior to screening
  3. Unwilling to discontinue contact lens.
  4. pregnancy or lactation.
  5. topical or nasal vasoconstrictors within 14 days prior to screening or unable to refrain from same.
  6. Ocular surgery or eyelid surgery within 6 months prior to screening
  7. Subjects can be on the following medications if they have been on a stable dose for 12 weeks: loteprednol, tetracycline, omega 3, anticholinergics, anticonvulsants, antidepressants, retinoids, systemic immunosuppressives including oral , non-steroidals, antihistamines, mast cell stabilizers, punctal plugs, corticotropin repository or glaucoma medications.
  8. abstain from eyelast growth products containing prostaglandin
  9. Must not have had penetrating intraocular surgery, refractive surgery, cornea transplant, eyelid surgery within 6 months prior to Visit 1
  10. Febrile illness within 1 week
  11. Treatment with another investigational drug or intervention within one month
  12. History of herpetic keratitis.
  13. Serious or severe disease or uncontrolled medical condition that in the judgment of the investigator could confound study study assessments or limit compliance.
  14. Use of new prescription eyedrop within 90 days of screening.
  15. Change in systemic medication within 90 days of screening
  16. Anticipated relocation or extensive travel during study period. -
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Nanomicellular Cyclosporine 0.09 prior to surgery

    50 subjects receive nanomicellular cyclosporien 0.09% prior to elective ophthalmic surgery

    Drug: nanomicellular cyclosporine 0.09%

  • Active comparator
    Lifitegrast 5.0%

    50 subjects receive liftigrast 5.0% prior to elective ophthalmic surgery

    Drug: Lifitegrast

Interventions

  • topical ophthalmic drop prior to elective surgery for eligible patients

    Also known as: Cequa

  • topical ophthalmic drop prior to elective surgery for eligible patients

    Also known as: Xiidra

06

What researchers measure

Primary outcomes

  1. change in central corneal staining

    use of fluorescein staining to count at slit lamp actual number of central cornea spk

    Time frame: 90 days

Secondary outcomes

  1. change in OSDI questionnaire with additional questions of dysgeusia, blurriness and sensation of burning

    subjective improvement of symptoms and assessment of adverse events

    Time frame: 90 days

  2. change in corneal topography

    variation in measurements of corneal topography

    Time frame: 90 days

  3. change in Schirmers testing

    change in Schirmers testing

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No plan to share individual date with other researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Dec 2022, 34 months after the start.

Of 84 non-industry phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 34 months is above that.

Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2019
First posted
Nov 21, 2019
StartActual
Feb 1, 2020
Primary completionEst.
Dec 1, 2022
CompletionEst.
Dec 1, 2022
Last update
Oct 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04172961
Lead sponsor
Toyos Clinic
Responsible party
Sponsor
First posted
Nov 21, 2019
Start date
Feb 1, 2020
Primary completion
Dec 1, 2022 (estimated)
Completion
Dec 1, 2022 (estimated)
Last update
Oct 20, 2022

Study contacts

Rachel McQuiddy
Contact
rmcquiddy@toyosclinic.com
6153274015
Melissa Toyos, MD
Contact
mtoyos@toyosclinic.com
6153274015

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion